ClinicalTrials.gg
WithdrawnNCT05521087Updated Jun 22, 2025

A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

A Phase 1 interventional study of JNJ-75276617 and Fludarabine in Acute Leukemias, Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia, sponsored by Janssen Research & Development, LLC. Withdrawn. Open to participants aged 30 Days to 30 Years. Per ClinicalTrials.gov, last updated 2025-06-22.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Business Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
30 Days to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Leukemia, Myeloid, Acute by Johnson & Johnson — 2 open to participants now, 4 under way, 1 of them phase 3. Leukemia, Myeloid, Acute · Johnson & Johnson.

Enrollment
15th of 15
0 · median 88
Started
2025
with 4 others
Phase 1
9 of 15
1 open now
Registered
10th of 15
by date

Among the 15 studies in Leukemia, Myeloid, Acute by Johnson & Johnson, this one is the 15th largest by enrollment, is one of 5 that started in 2025, is one of 9 in phase 1, and was the 10th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

2 of the 15 studies in Leukemia, Myeloid, Acute by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 30 Days to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Leukemia, Myeloid, Acute by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2Ds) of JNJ-75276617 in combination with a conventional chemotherapy backbone in pediatric and young adult participants with relapsed/refractory acute leukemia harboring histone-lysine N-methyltransferase 2A1 ([KMT2A1], nucleophosmin 1 gene (NPM1), or nucleoporin alterations in Part 1 (Dose Escalation) and to further evaluate safety at the RP2D(s) of JNJ-75276617 in combination with chemotherapy in pediatric and young adult participants with relapsed/refractory acute leukemia harboring KMT2A1, NPM1, or nucleoporin alterations and safety at the RP2D(s) of JNJ-75276617 as monotherapy in a select low burden of disease cohort in Part 2 (Dose Expansion).

03

Conditions studied

  • Acute Leukemias
  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Acute Leukemia of Ambiguous Lineage
04

Who can participate

Ages eligible
30 Days to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute leukemia harboring histone-lysine N-methyltransferase 2A (KMT2A) or nucleophosmin 1 gene (NPM1) or nucleoporin (NUP98 or NUP214) alterations
  • Performance status greater than or equal to (>=) 50 by lansky scale (for participants less than [\<] 16 years of age) or >=50 percent (%) scale (for participants >=16 years of age)
  • Estimated or measured >= 60 milliliter per minute per 1.73 meter square (mL/min/1.73m\^2) based on the bed side schwartz formula

Exclusion criteria

Exclusion Criteria:

  • Received an hematopoietic transplant within 60 days of screening
  • Active acute of any grade or chronic graft-versus-host which is not well-controlled
  • Received therapy post hematopoietic transplant within 30 days of enrollment
  • Diagnosis of Down syndrome associated leukemia, acute promyelocytic leukemia, juvenile myelomonocytic leukemia
  • Diagnosis of fanconi anemia, kostmann syndrome, shwachman diamond syndrome, or any other known bone marrow failure syndrome
  • Prior exposure to menin-KMT2A inhibitors
  • Prior cancer immunotherapy (ie [that is], Chimeric Antigen Receptor-T Cell Therapy [CAR-T], inotuzumab, gemtuzumab ozogamicin) within 4 weeks prior to enrollment or blinatumomab within 2 weeks prior to enrollment. Additional prior cancer therapies must not be given within 4 weeks prior to enrollment or 5 half-lives of the agent (whichever is shorter)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Arm A: <2 Years Old

    Participants aged less than (\<) 2 years old in dose escalation portion of the study will receive JNJ-75276617 orally on a 28-day cycle. Starting dose of JNJ-75276617 is based on the adult dose from the ongoing study NCT04811560 with additional dose reductions based on age. Further dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by study evaluation team (SET) until the recommended Phase 2 Doses (RP2Ds) has been identified. Participants in dose expansion portion of the study will receive JNJ-75276617 orally at one of the RP2D(s) determined in dose escalation portion of the study, in 3 cohorts divided on the basis of disease diagnosis. Participants with acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (ALL) will receive conventional chemotherapy backbone regimen (dexamethasone, vincristine, pegaspargase, fludarabine, cytarabine and intrathecal chemotherapy) in combination with JNJ-75276617.

    Drug: JNJ-75276617 · Drug: Fludarabine · Drug: Cytarabine · Drug: Intrathecal Chemotherapy · Drug: Dexamethasone · Drug: Vincristine · Drug: Pegaspargase

  • Experimental
    Arm B: >=2 Years Old

    Participants aged greater than or equal to (\>=) 2 years old in dose escalation portion of the study will receive JNJ-75276617 orally on a 28-day cycle. Starting dose of JNJ-75276617 is based on the adult dose from the ongoing study NCT04811560 with additional dose reductions based on age. Further dose levels will be escalated based on the DLT evaluation by SET until the RP2Ds has been identified. Participants in dose expansion portion of the study will receive JNJ-75276617 orally at one of the RP2D(s) determined in dose escalation portion, in 3 cohorts divided on the basis of disease diagnosis. Participants with AML and B-cell ALL will receive conventional chemotherapy backbone regimen (dexamethasone, vincristine, pegaspargase, fludarabine, cytarabine and intrathecal chemotherapy) in combination with JNJ-75276617.

    Drug: JNJ-75276617 · Drug: Fludarabine · Drug: Cytarabine · Drug: Intrathecal Chemotherapy · Drug: Dexamethasone · Drug: Vincristine · Drug: Pegaspargase

Interventions

  • JNJ-75276617 will be administered orally.

  • Fludarabine chemotherapy will be administered as intravenous (IV) infusion for participants with AML.

  • Cytarabine chemotherapy will be administered as IV infusion for participants with AML.

  • DrugIntrathecal Chemotherapy

    Intrathecal chemotherapy will be administered as IV infusion for participants with AML or B-cell ALL.

  • Dexamethasone chemotherapy will be administered as IV infusion for participants with B-cell ALL.

  • Vincristine chemotherapy will be administered as IV infusion for participants with B-cell ALL.

  • Pegaspargase chemotherapy will be administered as IV infusion for participants with B-cell ALL.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

    Time frame: Up to 3 years 5 months

  2. Number of Participants with AEs by Severity

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

    Time frame: Up to 3 years 5 months

  3. Number of Participants with Dose-Limiting Toxicity (DLT)

    Percentage of participants with DLT will be assessed. The DLTs are specific adverse events related to JNJ-75276617 and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.

    Time frame: Cycle 1 (28 days)

Secondary outcomes

  1. Plasma Concentration of JNJ-75276617

    Plasma concentration of JNJ-75276617 will be reported.

    Time frame: Up to 3 years 5 months

  2. Number of Participants with Depletion of Leukemic Blasts

    Number of participants with depletion of leukemic blasts will be reported.

    Time frame: Up to 3 years 5 months

  3. Number of Participants with Differentiation of Leukemic Blasts

    Number of participants with differentiation of leukemic blasts will be reported.

    Time frame: Up to 3 years 5 months

  4. Changes in Expression of Menin-histone-lysine N-methyltransferase 2A (KMT2A) Target Genes or Genes Associated With Differentiation

    Changes in expression of menin-histone-lysine N-methyltransferase 2A (KMT2A) target genes or genes associated with differentiation will be reported.

    Time frame: Up to 3 years 5 months

  5. Overall Response Rate (ORR) per Response Criteria in Acute Myeloid Leukemia (AML)

    ORR is defined as the percentage of participants who achieve complete response (CR), CR with incomplete hematologic recovery (CRi) or CR with partial hematologic recovery (CRh) per the Response Criteria in AML.

    Time frame: Up to 3 years 5 months

  6. Overall Response Rate (ORR) per the Response Criteria in B-cell Acute Lymphoblastic Leukemia (ALL)

    ORR in participants with B-cell ALL is defined as the percentage of participants who achieve CR or CRi per the response criteria in B-cell ALL.

    Time frame: Up to 3 years 5 months

  7. Time to Response (TTR)

    TTR is defined for the responders as the time from the date of the first dose of JNJ-75276617 to the date of the first documented response.

    Time frame: Up to 3 years 5 months

  8. Duration of Response (DOR)

    DOR will be calculated among responders from the date of initial documentation of a response to the date of first documented evidence of relapse, as defined in the disease-specific response criteria, or death due to any cause, whichever occurs first.

    Time frame: Up to 3 years 5 months

  9. Percentage of Participants With Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

    Percentage of participants who receive an allogeneic HSCT after treatment will be reported.

    Time frame: Up to 3 years 5 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Sep 2026, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2022
First posted
Aug 30, 2022
StartEst.
Dec 26, 2025
Primary completionEst.
Sep 11, 2026
CompletionEst.
Jan 29, 2030
Last update
Jun 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05521087
Responsible party
Sponsor
First posted
Aug 30, 2022
Start date
Dec 26, 2025 (estimated)
Primary completion
Sep 11, 2026 (estimated)
Completion
Jan 29, 2030 (estimated)
Last update
Jun 22, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bleximenib

Start the discussion